I'm LongbridgeAI, I can summarize articles.JonesTrading analyst Boris Peaker reiterated a Buy rating on Context Therapeutics (CNTX) with a $7 price target. The bullish stance is driven by promising Phase I data for CTIM-76 in CLDN6-positive solid tumors and an attractive risk/reward profile. Peaker argues the recent stock pullback is excessive, citing unfair comparisons to Zymeworks' ZW191 program, and believes current market sentiment does not reflect the drug's potential.
JonesTrading analyst Boris Peaker has reiterated their bullish stance on CNTX stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Boris Peaker has given his Buy rating due to a combination of factors that, in his view, are not reflected in the current share price. He sees the latest Phase I results for CTIM-76 in CLDN6-positive solid tumors as promising, especially considering the heavily pre-treated nature of the patient group, and expects the dataset to mature further with upcoming readouts.
He also believes the recent pullback in CNTX shares is excessive, as investors appear to be drawing unfair comparisons to Zymeworks’ ZW191 program, which was studied in a less refractory population with fewer prior therapies and less prior ADC exposure. With CTIM-76 showing initial efficacy signals and a favorable tolerability profile in a difficult-to-treat cohort, he views the risk/reward as attractive and therefore reiterates a Buy rating with an unchanged $7 price target.